Featured Speakers

Speakers for this conference will be listed here as they are confirmed.
Please check back regularly for the latest updates.

Thomas W. Abrams, RPh, MBA, Director, Division of Drug Marketing, Advertising, and Communications, Office of Medical Policy, CDER, FDA

Kathryn J. Aikin, PhD, Social Science Analyst, Direct-to-Consumer Review Group, DDMAC, OMP, CDER, FDA

Minnie V. Baylor-Henry, JD, Vice President, Global Regulatory Affairs-OTC,
Johnson & Johnson/McNeil Consumer Healthcare

Alan R. Bennett, Partner, Ropes and Gray LLP

Diane E. Bieri, Senior Vice President and General Counsel, PhRMA

Jeffrey S. Bucholtz, Principal Deputy Assistant Attorney General, Civil Division, U.S. Department of Justice

Cathryn M. Clary, MD, MBA, Vice President, U.S. External Medical Affairs

Richard M. Cooper, Partner, Williams and Connolly LLP

Thomas E. Costa, Vice President, U.S. Pharmaceuticals Compliance

Kristin I. Davis, JD, Deputy Director, Division of Drug Marketing, Advertising, and Communications, Office of Medical Policy, CDER, FDA

Robert T. Dean, Direct-to-Consumer Review Group I, DDMAC, OMP, CDER, FDA

Bhavana Desai, Senior Director, Advertising and Promotion Compliance, Allergan, Inc.

Norman A. Drezin, RPh, JD, President, Drezin Consultants, LLC

Mark E. DuVal, JD, President, DuVal & Associates, P.A.

Douglas B. Farquhar, Principal, Hyman, Phelps & McNamara, P.C.

Linda Ballai Fischer, Senior Director, Regulatory Affairs, King Pharmaceuticals, Inc.

Ralph F. Hall, Counsel, Baker & Daniels, LLC, and, Distinguished Visiting Practitioner and Professor, University of Minnesota Law School

Sheila M. Hemeon-Heyer, JD, RAC, Vice President, Global Regulatory Affairs, Boston Scientific Corporation Inc.

Elenita Y. Ibarra-Pratt, RN, MPH, Branch Chief, Advertising and Promotional Labeling Branch (APLB), Division of Case Management  (DCM), Office of Compliance and Biologics Quality (OCBQ), CBER, FDA

John F. Kamp, PhD, Executive Director, Coalition for Healthcare Communication,
and, Of Counsel, Wiley Rein LLP

Paul T. Kim, Partner, Foley Hoag LLP

Coleen E. Klasmeier, Partner, Life Sciences Practice, Sidley Austin LLP

Daniel A. Kracov, Partner, Chair, FDA and Healthcare Practice, Arnold & Porter LLP

Mark C. Levy, Partner, Saul Ewing LLP

CAPT Jean R. Makie, MS, RD, Regulatory Review Officer, APLB, DCM,
OCBQ, CBER, FDA

Cathie S. Marshall, DVM, Consumer Safety Officer,Division of Compliance,
Office of Surveillance and Compliance, CVM, FDA

Pamela L. Mason, FACME, CCMEP, Director, Medical Education Grants, AstraZeneca Pharmaceuticals

M. Elizabeth McKenzie, PhD, Director, U.S. Regulatory Affairs, Pfizer Animal Health

Christopher Melluso, DVM, Supervisory Veterinary Medical Officer, Post-Approval Review Team, CVM, FDA

Michael A. Misocky, RPh, JD, President, Misocky Consulting Group, LLC

Nancy M. Ostrove, PhD, Senior Advisor for Risk Communications, Office of Planning,
Office of Policy, Planning and Preparedness, Office of the Commissioner, FDA

Wayne L. Pines, President, Regulatory Services and Healthcare, APCO Worldwide

Mary E. Riordan, Senior Counsel, Administrative and Civil Remedies Branch, Office of Inspector General, U.S. Department of Health and Human Services

Janet Lucy Rose, National Managing Director, Life Sciences Regulatory
and Capital Markets Consulting, Deloitte & Touche, LLP

Hilary J. Schmidt, PhD, Associate Vice President, Medical Education, Sanofi-Aventis

Jeffrey M. Senger, Deputy Chief Counsel, Office of the Chief Counsel, FDA

Lynn Shapiro Snyder, Senior Member, Epstein Becker & Green, P.C.

Ann L. Simoneau, RPh, JD, MBA, Regulatory Counsel, Promotion and Advertising Policy Staff, Office of Compliance, CDRH, FDA

Jennifer Spear Smith, PhD, FACME, Executive Director, Professional Education Support, Wyeth Pharmaceuticals

Nadine R. Steinberg, Supervisory Regulatory Counsel, Office of Surveillance and Compliance, CVM, FDA

Lauren C. Stevens, Vice President and Associate General Counsel, GlaxoSmithKline

Michael T. Van Koevering, PhD, Manager, Regulatory Compliance, Elanco Animal Health

Ann M. Witt, Health Counsel, Committee on Oversight and Government Reform, U.S. House of Representatives

Copyright © 2008, The Food and Drug Law Institute    
1155 15 Street NW, Suite 800 | Washington, DC | 20005    
phone (800) 956-6293 | (202) 371-1420 | fax (202) 371-0649    
comments@fdli.org